A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Uncategorized

  • Major Bleeding on Dabigatran (Pradaxa) – Interesting Publication

    Stephan Moll, MD writes… Interesting publication this week in Circulation: “Management and outcomes of major bleeding during treatment with dabigatran or warfarin” (Majeed A et al; published online Sept 30,2013;  full publication is here).  The management and prognosis of major bleeding in patients treated with dabigatran or warfarin was compared, pooling data of the major bleeds that occurred in 5 phase III…

  • NEJM Publication: Edoxaban for VTE Treatment

    Stephan Moll, MD writes…  Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

  • New Oral Anticoagulants for DVT and PE: Update on FDA Applications

    Stephan Moll, MD writes…   1.  Pradaxa (Dabigatran) Today, August 28th, 2013, it was announced that the FDA is reviewing the application by Boehringer-Ingelheim to get Pradaxa (dabigatran) approved for use in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) – details here. At present, in the US, Pradaxa is only FDA-approved for…

  • International Coagulation Meeting (ISTH 2013): Highlights

    Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

  • New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE

    Stephan Moll, MD writes…   An important study (AMPLIFY trial) was published today in the New England Journal of Medicine [ref 1]: In a large study of 5395 patients with acute DVT or PE, Eliquis (apixaban) was as effective as warfarin and caused less major bleeding.

  • Skyla – A New IUD, Suitable for Women at Risk for DVT and PE

    Dr. Stephan Moll writes… Skyla® is a new IUD (intrauterine device) contraceptive, approved in February 2013 by the FDA.  Skyla® is like a small version of the Mirena® IUD.  It has the following features:

  • Difficulty in Diagnosing Recurrent DVT – Clinical Guidance

    Stephan Moll, MD writes….  Recurrent DVT can be challenging to diagnose, as it may be difficult on Doppler ultrasound to tell chronic changes from additional new clot.  A guidance statement from the ISTH (International Society for Thrombosis and Haemostasis) published this week (May 18th, 2013) provides solid, clinically useful, evidence-based recommendations

  • New Clinical-Practical Textbook on Hemostasis and Thrombosis

    Stephan Moll, MD writes…. Freshly published just now (May 2013), the 3rd edition of the very clinical-practical Consultative Hemostasis and Thrombosis textbook edited by Kitchens, Kessler & Konkle – link here.  822 pages, 47 chapters on bleeding and clotting disorders, diagnosis, management.  Suitable for whom?  Useful as a reference for all practicing physicians and midlevel providers who…